Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03306277 · ClinicalTrials.gov registry record · Phase 3
Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1
A Phase 3 study, sponsored by Novartis Gene Therapies.
- Completed
- Registry status
- Phase 3
- Development phase
- 22
- Enrollment target
NCT03306277 is a Phase 3 study that has completed, run by Novartis Gene Therapies. The registered enrollment target is 22 participants.
The verdict
NCT03306277, a Phase 3 study, has completed, sponsored by Novartis Gene Therapies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 22 participants
- Enrollment target
Study Summary
Phase 3 pivotal US trial studying open-label intravenous administration of onasemnogene abeparvovec-xioi in spinal muscular atrophy (SMA) Type 1 participants.
Interventions
- BIOLOGICAL Onasemnogene Abeparvovec-xioi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2017-10-24 |
| Est. Completion | 2019-11-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03306277
The ClinicalTrials.gov registry entry for NCT03306277 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Gene Therapies, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Onasemnogene Abeparvovec-xioi is the first listed.
NCT03306277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03306277 about?
NCT03306277 is a clinical study titled "Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1". Phase 3 pivotal US trial studying open-label intravenous administration of onasemnogene abeparvovec-xioi in spinal muscular atrophy (SMA) Type 1 participants.
What is the current status of trial NCT03306277?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 22 participants. The study started on 2017-10-24. Estimated completion is 2019-11-12.
What interventions are being tested in trial NCT03306277?
The interventions under investigation include: Onasemnogene Abeparvovec-xioi (BIOLOGICAL).
Who is sponsoring clinical trial NCT03306277?
This trial is sponsored by Novartis Gene Therapies, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.